• Innocan Pharma Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells
    Read more
  • Innocan Pharma: Veröffentlichung von zwei Studien, die den CLX-Therapieansatz des Unternehmens für mit COVID-19 infizierte Lungenzellen unterstützen
    Read more
  • Innocan Pharma's Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief &Go OTC Pain Relief Spray
    Read more
  • Klinische Studie von Innocan Pharma in den USA: Schmerzlinderung bei mehr als 90 % der Probanden nach Anwendung von Innocans rezeptfreiem Relief & Go-Schmerzlinderungsspray
    Read more
  • Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum
    Read more
  • Klinische Kosmetikstudie von Innocan Pharma: 90 % Faltenreduktion nach Anwendung des Premium-CBD-Gesichtsserums SHIR ™
    Read more
  • Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD
    Read more
  • Innocan erzielt in der Entwicklung seiner einzigartigen, mit CBD beladenen Liposomen-Plattform-Technologie für injizierbares CBD einen wichtigen Meilenstein
    Read more
  • Innocan Pharma to Provide a Corporate Update via Livestream Video
    Read more
  • InnoCan Pharma Corporation: Innocan Pharma informiert am 14. Oktober 2020 um 10 Uhr EST in einem Livestream-Video über Neuigkeiten aus dem Unternehmen
    Read more
  • Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration
    Read more
  • Innocan Pharma schließt erfolgreiche kosmetische klinische Studien ab, die Wirksamkeit seines Premium-CBD-Gesichtsserums SHIRTM hinsichtlich Hautfeuchtigkeit belegen
    Read more
  • Innocan Pharma to Amend Warrants Held by Tamar Technologies Ltd.
    Read more
  • Innocan Pharma Announces Publication of Enterprise Report by Mackie Research
    Read more
  • Innocan Pharma meldet Veröffentlichung eines Berichts zum Unternehmen durch Mackie Research
    Read more
  • Innocan to Distribute Its CBD Line of Products in Italy and Switzerland
    Read more
  • InnoCan Pharma Corporation: Innocan wird seine CBD-Produktlinie in Italien und der Schweiz auf den Markt bringen
    Read more
  • Innocan Engages Endless Sky to Manufacture and Distribute Innocan's CBD Cosmetic Products in Canada
    Read more
  • Innocan beauftragt Endless Sky mit der Herstellung und dem Vertrieb der CBD-Kosmetikprodukte von Innocan in Kanada
    Read more
  • Innocan's SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union
    Read more
  • Innocans CBD-Hautpflege-Kosmetikprodukte der Marke SHIRTM Beauty & Science haben die Sicherheitsprüfung erfolgreich bestanden und wurden für den Markt der Europäischen Union zugelassen
    Read more
  • Innocan's Over-The-Counter Pain Relief Spray Receives FDA's Technical Validation for Marketing in the USA
    Read more
  • Innocans rezeptfrei erhältlicher schmerzstillender Spray hat die fachliche Validierung der FDA für die Vermarktung in den USA erfolgreich bestanden
    Read more
  • InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments
    Read more
  • Innocan Pharma kooperiert in der Entwicklung von Therapien mit CBD beladenen Exosomen (CLX) mit der Firma Recipharm
    Read more
  • Innocan Pharma's Corporate Update
    Read more
  • InnoCan Pharma Announces the Successful Completion of an Independent Clinical Study Demonstrating Safety and Skin Tolerance of Its CBD Derma Cosmetic Line
    Read more
  • IRW-News: InnoCan Pharma Corporation: InnoCan Pharma meldet erfolgreichen Abschluss einer klinischen Studie zur Sicherheit und Hautverträglichkeit seiner kosmetischen Hautpflegeprodukte
    Read more
  • Innocan Pharma meldet Veröffentlichung eines Berichts zum Unternehmen durch die Institutional Sales Group von Mackie Research
    Read more
  • Innocan Pharma Announces Mackie Research's Institutional Sales Group Issues Enterprise Publication on the Company
    Read more
  • InnoCan unterzeichnet Absichtserklärung mit Tamar und sichert sich Vertrieb und Lieferung von aktivem CBD-Wirkstoff für den Einsatz in InnoCans Forschungsprojekten
    Read more
  • InnoCan Signs Letter of Intent with Tamar to Distribute and Supply CBD "API" for use in InnoCan's Research Projects
    Read more
  • Innocan Pharma gibt den Abschluss einer 5,1-Millionen-Dollar-Platzierung von Einheiten mit Prospekt bekannt
    Read more
  • Innocan Pharma Announces Closing of $5.1 Million Prospectus Offering of Units
    Read more
  • InnoCan Pharma beginnt mit kommerzieller Produktion seiner CBD-integrierten Derma-Produktlinie in Portugal
    Read more
  • InnoCan Pharma Announced the Commencement of its Derma CBD Line Commercial Production in Portugal
    Read more
  • Innocan Pharma Amends Terms of Marketed Short Form Prospectus Offering of Units
    Read more
  • InnoCan Pharma unterzeichnet Absichtserklärung zur Entwicklung und Herstellung von Exosomen für den Einsatz im Rahmen seiner Therapien mit CBD beladenen Exosomen (CLX)
    Read more
  • InnoCan Pharma Enters into Letter of Intent to Develop and Produce Exosomes for Use in its CBD-Loaded Exosome (CLX) Treatments
    Read more
  • Innocan Pharma Announces Pricing of Marketed Short Form Prospectus Offering of Units
    Read more
  • Innocan Pharma Announces up to $10 Million Public Offering of Units
    Read more
  • InnoCan Announces Appointment of Professor Daniel Offen, Scientific Advisory Director
    Read more
  • InnoCan to Develop a New Lines of CBD Products for Tamar Technologies
    Read more
  • InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
    Read more
  • InnoCan Provides Update and Summary About Its Corporate Progress as Its First Products Prepare to Enter the Commercial Marketplace
    Read more
  • InnoCan Pharma Announces Patent Application for Novel Hemorrhoid Treatment
    Read more
  • InnoCan Signs its First Distribution Agreement with "Active Therapeutics" for InnoCan's CBD Derma Cosmetics products in the United Kingdom and Ireland
    Read more
  • InnoCan Announces Appointment of Prominent Healthcare Executive, Peter Bloch as a Director
    Read more
  • InnoCan Announces It Has Executed A Research & License Agreement With The Commercial Arm Of The Hebrew University
    Read more
  • InnoCan Announces Successful Research Study Advancing Its Development of Cannabidiol Targeted Injection Delivery Platform
    Read more
  • INNOCAN SIGNS AGREEMENT TO MANUFACTURE PRODUCTS IN THE U.S.
    Read more
  • INNOCAN PHARMA SIGNS AN AGREEMENT WITH FANCYSTAGE UNIPESSOAL LDA
    Read more
  • INNOCAN PHARMA PLANS TO ENTER CBD BEAUTY MARKET WITH LAUNCH OF INNOCAN BRANDED COSMETIC PRODUCTS IN H1/20
    Read more
  • INNOCAN PHARMA ANNOUNCES PATENT APPLICATION TO ENABLE CBD TARGETED INJECTIONS
    Read more
  • Innocan Pharma Corporation Announces Closing of Initial Public Offering and Listing on Canadian Securities Exchange Under the Symbol “Inno”
    Read more